Fevipiprant

Fevipiprant

• CAS Number: 872365-14-5
• UNSPSC Description: Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an Kd value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma[1][2][3].
• Target Antigen: CRTH2 (GPR44); Prostaglandin Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Immunology/Inflammation
• Applications: Cancer-programmed cell death
• Field of Research: Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/Fevipiprant.html
• Solubility: DMSO : ≥ 32 mg/mL
• Smiles: O=C(O)CC1=C(C)N(CC2=CC=C(S(=O)(C)=O)C=C2C(F)(F)F)C3=NC=CC=C31
• Molecular Weight: 426.41
• References & Citations: [1]Brightling C, et al. The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulm Pharmacol Ther. 2021 Jun;68:102030.|[2]Lee HY, et al. Blockade of thymic stromal lymphopoietin and CRTH2 attenuates airway inflammation in a murine model of allergic asthma. Korean J Intern Med. 2020 May;35(3):619-629. |[3]Weintraub NL, et al. Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation. Clin Sci (Lond). 2022 Mar 18;136(5):309-321.
• Shipping Conditions: Room Temperature
• Clinical Information: Phase 3